Literature DB >> 21415363

Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity.

Paul A Wender1, Jeremy L Baryza, Stacey E Brenner, Brian A DeChristopher, Brian A Loy, Adam J Schrier, Vishal A Verma.   

Abstract

Modern methods for the identification of therapeutic leads include chemical or virtual screening of compound libraries. Nature's library represents a vast and diverse source of leads, often exhibiting exquisite biological activities. However, the advancement of natural product leads into the clinic is often impeded by their scarcity, complexity, and nonoptimal properties or efficacy as well as the challenges associated with their synthesis or modification. Function-oriented synthesis represents a strategy to address these issues through the design of simpler and therefore synthetically more accessible analogs that incorporate the activity-determining features of the natural product leads. This study illustrates the application of this strategy to the design and synthesis of functional analogs of the bryostatin marine natural products. It is specifically directed at exploring the activity-determining role of bryostatin A-ring functionality on PKC affinity and selectivity. The resultant functional analogs, which were prepared by a flexible, modular synthetic strategy, exhibit excellent affinity to PKC and differential isoform selectivity. These and related studies provide the basic information needed for the design of simplified and thus synthetically more accessible functional analogs that target PKC isoforms, major targets of therapeutic interest.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21415363      PMCID: PMC3084132          DOI: 10.1073/pnas.1015270108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  68 in total

Review 1.  Target-oriented and diversity-oriented organic synthesis in drug discovery.

Authors:  S L Schreiber
Journal:  Science       Date:  2000-03-17       Impact factor: 47.728

2.  Design, synthesis, and biological evaluation of a potent, PKC selective, B-ring analog of bryostatin.

Authors:  Paul A Wender; Vishal A Verma
Journal:  Org Lett       Date:  2006-04-27       Impact factor: 6.005

Review 3.  Targeting the protein kinase C family: are we there yet?

Authors:  Helen J Mackay; Christopher J Twelves
Journal:  Nat Rev Cancer       Date:  2007-07       Impact factor: 60.716

Review 4.  Rationally designed peptide regulators of protein kinase C.

Authors:  Eric N Churchill; Nir Qvit; Daria Mochly-Rosen
Journal:  Trends Endocrinol Metab       Date:  2008-12-04       Impact factor: 12.015

5.  The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity.

Authors:  Paul A Wender; Vishal A Verma
Journal:  Org Lett       Date:  2008-06-28       Impact factor: 6.005

6.  A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma.

Authors:  Jaffer A Ajani; Yixing Jiang; Josephine Faust; Baochong B Chang; Linus Ho; James C Yao; Steven Rousey; Shaker Dakhil; Richard C Cherny; Catherine Craig; Archie Bleyer
Journal:  Invest New Drugs       Date:  2006-07       Impact factor: 3.850

7.  Function-oriented synthesis of simplified caprazamycins: discovery of oxazolidine-containing uridine derivatives as antibacterial agents against drug-resistant bacteria.

Authors:  Kensuke Ii; Satoshi Ichikawa; Bayan Al-Dabbagh; Ahmed Bouhss; Akira Matsuda
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

Review 8.  Function-oriented synthesis, step economy, and drug design.

Authors:  Paul A Wender; Vishal A Verma; Thomas J Paxton; Thomas H Pillow
Journal:  Acc Chem Res       Date:  2007-12-27       Impact factor: 22.384

9.  Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice.

Authors:  René Etcheberrigaray; Mathew Tan; Ilse Dewachter; Cuno Kuipéri; Ingrid Van der Auwera; Stefaan Wera; Lixin Qiao; Barry Bank; Thomas J Nelson; Alan P Kozikowski; Fred Van Leuven; Daniel L Alkon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-19       Impact factor: 11.205

10.  Potent cytotoxins produced by a microbial symbiont protect host larvae from predation.

Authors:  Nicole Lopanik; Niels Lindquist; Nancy Targett
Journal:  Oecologia       Date:  2004-01-28       Impact factor: 3.225

View more
  35 in total

Review 1.  Microbial natural products: molecular blueprints for antitumor drugs.

Authors:  Lesley-Ann Giddings; David J Newman
Journal:  J Ind Microbiol Biotechnol       Date:  2013-09-03       Impact factor: 3.346

2.  Toward the Ideal Synthesis and Transformative Therapies: The Roles of Step Economy and Function Oriented Synthesis.

Authors:  Paul A Wender
Journal:  Tetrahedron       Date:  2013-06-07       Impact factor: 2.457

3.  Bürgenstock 2012: Reflections on stereochemistry.

Authors:  Stuart J Conway
Journal:  Nat Chem       Date:  2013-02       Impact factor: 24.427

4.  Lead Diversification through a Prins-Driven Macrocyclization Strategy: Application to C13-Diversified Bryostatin Analogues.

Authors:  Paul A Wender; Kelvin L Billingsley
Journal:  Synthesis (Stuttg)       Date:  2013       Impact factor: 3.157

5.  Total synthesis of bryostatin 9.

Authors:  Paul A Wender; Adam J Schrier
Journal:  J Am Chem Soc       Date:  2011-05-27       Impact factor: 15.419

6.  Function Oriented Synthesis: Preparation and Initial Biological Evaluation of New A-Ring-Modified Bryologs.

Authors:  Paul A Wender; Jenny Reuber
Journal:  Tetrahedron       Date:  2011-12-23       Impact factor: 2.457

7.  Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.

Authors:  N Kedei; A Telek; A M Michalowski; M B Kraft; W Li; Y B Poudel; A Rudra; M E Petersen; G E Keck; P M Blumberg
Journal:  Biochem Pharmacol       Date:  2012-11-09       Impact factor: 5.858

Review 8.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

9.  Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription.

Authors:  Koen Bartholomeeusen; Koh Fujinaga; Yanhui Xiang; B Matija Peterlin
Journal:  J Biol Chem       Date:  2013-03-28       Impact factor: 5.157

10.  Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C-C Bond Formation: Potency Does Not Confer Bryostatin-like Biology.

Authors:  John M Ketcham; Ivan Volchkov; Te-Yu Chen; Peter M Blumberg; Noemi Kedei; Nancy E Lewin; Michael J Krische
Journal:  J Am Chem Soc       Date:  2016-09-27       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.